Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University?s College of Education.
Reclast? (zoledronic acid) Injection has been approved by the US Food and Drug Administration as the first and only once-yearly medicine for postmenopausal osteoporosis, offering an important new approach to the treatment of a bone disease affecting eight million women in the US.
Due in large part to strong competitive bidding by health and prescription drug plans and beneficiaries? choices, the Centers for Medicare & Medicaid Services (CMS) anticipates that the actual average premium paid by beneficiaries for standard Part D coverage in 2008 will be roughly $25.
Most American adults don’t exercise enough, but updated national guidelines for physical fitness allow for flexibility and will make it easier to determine how much is enough to maintain good health, according to Health Fitness Corporation (HFC) (OTC Bulletin Board: HFIT), a national leader in worksite health management.
A major focus in the search for accountability in the US health care system is new reimbursement and benefit models that provide incentives better linked to positive health outcomes. A recent study found some valuable lessons from a model in Maine that tied some degree of risk and reward for both health care providers and employer/purchasers.
Clamping and cutting of the umbilical cord should be delayed for three minutes after birth, particularly for pre-term infants, suggests a senior doctor in this week?s BMJ.
An 88-year-old man at The Methodist Hospital in Houston is one of two patients in the world today to receive an investigational eye drop that may restore sight for those suffering from neovascular (wet) age-related macular degeneration, a major cause of central visual loss and one of the leading causes of blindness in people over 60 in the United States.
The use of ‘decision support’ computer software can significantly improve the management of patients concerned about their family history of breast and bowel cancer, according to a study published in the British Journal of Cancer* today (Tuesday).
An innovative Hobart company has developed a system for hospitals and clinics which will prove invaluable in the management of chronic diseases.
As of 10_August 2007, the Therapeutic Goods Administration, Australia, TGA had received eight reports of serious liver adverse reactions associated with use of lumiracoxib, including two deaths and two patients requiring liver transplants.